The effect of LMWH (Nadroparin) on tumor progression

Z. Nagy, Vera Turcsik, György Blaskó

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.

Original languageEnglish
Pages (from-to)689-692
Number of pages4
JournalPathology and Oncology Research
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Nadroparin
Low Molecular Weight Heparin
Neoplasms
Thromboembolism
Anticoagulants
Retrospective Studies
Control Groups
Survival
Therapeutics

Keywords

  • LMWH
  • Nadroparin
  • Survival
  • Tumor progression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

The effect of LMWH (Nadroparin) on tumor progression. / Nagy, Z.; Turcsik, Vera; Blaskó, György.

In: Pathology and Oncology Research, Vol. 15, No. 4, 12.2009, p. 689-692.

Research output: Contribution to journalArticle

Nagy, Z. ; Turcsik, Vera ; Blaskó, György. / The effect of LMWH (Nadroparin) on tumor progression. In: Pathology and Oncology Research. 2009 ; Vol. 15, No. 4. pp. 689-692.
@article{5fddb8a1f06f465bbd6e98dacadba964,
title = "The effect of LMWH (Nadroparin) on tumor progression",
abstract = "Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.",
keywords = "LMWH, Nadroparin, Survival, Tumor progression",
author = "Z. Nagy and Vera Turcsik and Gy{\"o}rgy Blask{\'o}",
year = "2009",
month = "12",
doi = "10.1007/s12253-009-9204-7",
language = "English",
volume = "15",
pages = "689--692",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - The effect of LMWH (Nadroparin) on tumor progression

AU - Nagy, Z.

AU - Turcsik, Vera

AU - Blaskó, György

PY - 2009/12

Y1 - 2009/12

N2 - Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.

AB - Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.

KW - LMWH

KW - Nadroparin

KW - Survival

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=74949103246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949103246&partnerID=8YFLogxK

U2 - 10.1007/s12253-009-9204-7

DO - 10.1007/s12253-009-9204-7

M3 - Article

VL - 15

SP - 689

EP - 692

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 4

ER -